Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors

World Journal of Gastroenterology

Volumn 17, Issue 2, 2011, Pages 219-225

  Kuiper, Patricia ^a   Hawinkels, Lukas J A C ^a   de Jonge Muller, Eveline S M ^a   Biemond, Izäk ^a   Lamers, Cornelis B H W ^a   Verspaget, Hein W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Angiogenesis factors; Carcinoid tumor; Endoglin; Neuroendocrine tumor; Vascular endothelial growth factor

Indexed keywords

CD31 ANTIGEN; ENDOGLIN; VASCULOTROPIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTRINOMA; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; MALE; MICROVASCULATURE; NEUROENDOCRINE TUMOR; PROTEIN EXPRESSION; TISSUE LEVEL; TUMOR VOLUME;

EID: 79955618719     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i2.219     Document Type: Article

References (27)

1. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer 2004; 11: 1-18
2. Poncet G, Villaume K, Walter T, Pourreyron C, Theillaumas A, Lépinasse F, Hervieu V, Cordier-Bussat M, Scoazec JY, Roche C. Angiogenesis and tumor progression in neuroendocrine digestive tumors. J Surg Res 2009; 154: 68-77
3. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974; 19: 331-358
4. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211-220
5. Strosberg JR, Kvols LK. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Investig Drugs 2007; 16: 219-224
6. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26: 1316-1323
7. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, Verheijen JH, Hommes DW, Lamers CB, Sier CF. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer 2007; 97: 398-404
8. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 2001; 52: 437-449
9. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. En-doglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene 2003; 22: 6557-6563
10. Zijlmans HJ, Fleuren GJ, Hazelbag S, Sier CF, Dreef EJ, Kenter GG, Gorter A. Expression of endoglin (CD105) in cervical cancer. Br J Cancer 2009; 100: 1617-1626
11. Yoshitomi H, Kobayashi S, Ohtsuka M, Kimura F, Shimizu H, Yoshidome H, Miyazaki M. Specifc expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 2008; 37: 275-281
12. Romani AA, Borghetti AF, Del Rio P, Sianesi M, Soliani P. The risk of developing metastatic disease in colorectal cancer is related to CD105-positive vessel count. J Surg Oncol 2006; 93: 446-455
13. Rindi G, Klöppel G. Endocrine tumors of the gut and pancreas tumor biology and classifcation. Neuroendocrinology 2004; 80 Suppl 1: 12-15
14. Hawinkels LJ, Kuiper P, Wiercinska E, Verspaget HW, Liu Z, Pardali E, Sier CF, Ten Dijke P. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor an-giogenesis. Cancer Res 2010; 70: 4141-4150
15. Lowry OH, Rosebrough NJ, Farr AL, RANDALL RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275
16. Hawinkels LJ, Zuidwijk K, Verspaget HW, de Jonge-Muller ES, van Duijn W, Ferreira V, Fontijn RD, David G, Hommes DW, Lamers CB, Sier CF. VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angio-genesis. Eur J Cancer 2008; 44: 1904-1913
17. Quesada AR, Muñoz-Chápuli R, Medina MA. Anti-angio-genic drugs: from bench to clinical trials. Med Res Rev 2006; 26: 483-530
18. Nussenbaum F, Herman IM. Tumor angiogenesis: insights and innovations. J Oncol 2010; 2010: 132641
19. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409
20. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angio-genesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8
21. Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M. Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res 2010; 86: 12-19
22. Zhang J, Jia Z, Li Q, Wang L, Rashid A, Zhu Z, Evans DB, Vauthey JN, Xie K, Yao JC. Elevated expression of vascular en-dothelial growth factor correlates with increased angiogenesis and decreased progression-free survival among patients with low-grade neuroendocrine tumors. Cancer 2007; 109: 1478-1486
23. Takahashi Y, Akishima-Fukasawa Y, Kobayashi N, Sano T, Kosuge T, Nimura Y, Kanai Y, Hiraoka N. Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors. Clin Cancer Res 2007; 13: 187-196
24. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520
25. Bernabeu C, Lopez-Novoa JM, Quintanilla M. The emerging role of TGF-beta superfamily coreceptors in cancer. Biochim Biophys Acta 2009; 1792: 954-973
26. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008; 9: 61-72
27. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135: 1469-1492